Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Port Wine Stain Clear all
Completed No phase listed Observational Results available

CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness

NCT03652181
View directory record Official record
Conditions
CCM, Cavernoma, Cerebral Cavernous Malformation, Cerebral Cavernous Malformations 1, Cerebral Cavernous Malformations 2, Cerebral Cavernous Malformations 3, Cavernous Angioma
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Phase 1 Interventional

Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)

NCT02108002
View directory record Official record
Conditions
Von Hippel-Lindau Disease
Interventions
Vorinostat
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Sep 9, 2026, 8:30 AM EDT
Terminated Phase 2 Interventional Results available

TKI 258 in Von Hippel-Lindau Syndrome (VHL)

NCT01266070
View directory record Official record
Conditions
Von Hippel-Lindau Syndrome
Interventions
Dovitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2017 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Not applicable Interventional Results available

Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment

NCT01775722
View directory record Official record
Conditions
Port-Wine Stain
Interventions
Pulsed Dye Laser, Combined Bipolar Radiofrequency&Pulsed Dye Laser
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 9, 2026, 8:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dynamic Epidermal Cooling During Pulsed Dye Laser Treatment of Port Wine Stain Birthmark at High Fluences

NCT00540371
View directory record Official record
Conditions
Port Wine Stain
Interventions
Port wine stain Birthmark
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
1 Month to 75 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

NCT00589784
View directory record Official record
Conditions
CNS Cancer, Meningioma, Intracranial Hemangiopericytoma, Hemangioblastoma, Neurofibromatosis
Interventions
Sunitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
6
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced Sep 9, 2026, 8:30 AM EDT
Recruiting Not applicable Interventional

Maximizing Laser Therapy Success for Port-Wine Birthmarks in Pediatric Patients

NCT07183644
View directory record Official record
Conditions
Port Wine Stains
Interventions
Pulse Dye laser, Pulse Dye Laser (PDL) pulse width stacking, Pulse Dye Laser (PDL) followed by Nd:YAG (Neodymium-doped Yttrium Aluminum Garnet laser) laser., IPL (Intense Pulsed Light) followed by Pulse Dye Laser (PDL), Cupping followed by Pulse Dye Laser (PDL)
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Months to 18 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584

NCT00052013
View directory record Official record
Conditions
Von Hippel-Lindau Disease, CNS Hemangioblastoma, Retinal Hemangioblastoma
Interventions
PTK787/ZK 222584
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pathogenic Mechanisms of Port Wine Stain and Repository of Port Wine Stain Biopsy Samples

NCT02051101
View directory record Official record
Conditions
Port-Wine Stain
Interventions
Biopsy sample from Port Wine Stain Birthmark
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
1 Day and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 9, 2026, 8:30 AM EDT
Terminated Phase 2 Interventional Results available

The Effects of Aldara as an Adjunct to Laser Treatment

NCT00979550
View directory record Official record
Conditions
Port Wine Stains
Interventions
Imiquimod, non-medicated petroleum cream
Drug
Lead sponsor
Henry Vasconez
Other
Eligibility
2 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 9, 2026, 8:30 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 9, 2026, 8:30 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn

NCT01873131
View directory record Official record
Conditions
Hemangioma
Interventions
topical timolol maleate, Pulsed dye laser
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Up to 3 Months
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Not applicable Interventional Results available

Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains

NCT00556946
View directory record Official record
Conditions
Port Wine Stains
Interventions
Combined Photodynamic & Pulsed Dye Laser Treatment
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Sep 9, 2026, 8:30 AM EDT
Not listed Early Phase 1 Interventional

Topical Simvastatin for Treating Infantile Hemangioma

NCT06273111
View directory record Official record
Conditions
Hemangioma Skin
Interventions
5% simvastatin ointment
Drug
Lead sponsor
Joyce Teng
Other
Eligibility
3 Months to 5 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 9, 2026, 8:30 AM EDT
Recruiting Phase 4 Interventional

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.

NCT04081701
View directory record Official record
Conditions
CNS Tumors, Meningioma, Esthesioneuroblastoma, Hemangioblastoma, Medulloblastoma, Paraganglioma, Pituitary Adenoma
Interventions
Ga68-DOTATATE-PET/MRI
Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab

NCT02859441
View directory record Official record
Conditions
Von Hippel-Lindau Syndrome
Interventions
Ranibizumab, E10030
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 9, 2026, 8:30 AM EDT
Withdrawn No phase listed Observational

Optical Frequency Domain Imaging (OFDI) in Dermatology

NCT01438047
View directory record Official record
Conditions
Port Wine Stain
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy

NCT01056341
View directory record Official record
Conditions
Infantile Hemangioma
Interventions
Propranolol, Placebo
Drug
Lead sponsor
Pierre Fabre Dermatology
Industry
Eligibility
35 Days to 150 Days
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Irvine, California • Redwood City, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Sep 9, 2026, 8:30 AM EDT
Withdrawn No phase listed Observational

Effect of Laser Treatment on Capillary Malformations

NCT02035319
View directory record Official record
Conditions
Capillary Malformation, Port Wine Stain
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Sep 9, 2026, 8:30 AM EDT
Withdrawn Phase 2 Interventional

Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)

NCT01408056
View directory record Official record
Conditions
Infantile Hemangiomas
Interventions
Timolol 0.5% Gel Forming Solution (GFS), Mupirocin 2% Ointment
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 8 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Phase 1 Interventional

Novel Treatment for Port Wine Stain Birthmarks

NCT01924273
View directory record Official record
Conditions
Port-Wine Stain
Interventions
Talaporfin sodium
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 9, 2026, 8:30 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)

NCT02913612
View directory record Official record
Conditions
Infantile Hemangioma
Interventions
0.25% Timolol Maleate Gel Forming Solution, 0.5% Timolol Maleate Gel Forming Solution
Drug
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
Up to 84 Days
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
12
States / cities
Chicago, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 9, 2026, 8:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hemangioma Growth During the First 6 Months of Life

NCT00911781
View directory record Official record
Conditions
Hemangiomas of Infancy
Interventions
No intervention
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Months to 5 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
San Francisco, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 9, 2026, 8:30 AM EDT
Terminated Early Phase 1 Interventional Results available

Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas

NCT01147601
View directory record Official record
Conditions
Hemangioma, Infant
Interventions
topical 0.5% Timolol, Control (placebo) group
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Month to 8 Months
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 4, 2017 · Synced Sep 9, 2026, 8:30 AM EDT